Best Practice & Research Clinical Rheumatology
Volume 23, Issue 1 , Pages 83-92 , February 2009

The economics of treatment in early rheumatoid arthritis

  • Nick Bansback, MSc

      Affiliations

    • Centre for Health Evaluation and Outcome Sciences, St Paul's Hospital, Vancouver, BC, Canada V6Z 1Y6, Canada
    • ,
  • Carlo A. Marra, PharmD, PhD (Assistant Professor and Director of CORE)

      Affiliations

    • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
    • ,
  • Axel Finckh, MD, MS

      Affiliations

    • Division of Rheumatology, University Hospital of Geneva, 26 Av. Beau-Sejour, CH -1211 Geneva 14, Switzerland
    • ,
  • Aslam Anis, PhD (Professor and Director of CHEOS)

      Affiliations

    • Department of Health Care and Epidemiology, Faculty of Medicine, University of British Columbia, James Mather Building 5804 Fairview Avenue, Vancouver, BC, Canada V6T 1Z3
    • Corresponding Author InformationCorresponding author. Tel.: +1 604 822 5550; Fax: +1 604 822 4994.

References 

  1. Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol. 2007;21(5):929–942
  2. Dunlop DD, Manheim LM, Yelin EH, et al. The costs of arthritis. Arthritis Care Res. 2003;49(1):101–113
  3. Landewe RBM, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347–356
  4. Bansback NJ, Regier DA, Ara R, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-[alpha] antagonists. Drugs. 2005;65(4):473
  5. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 2006 Dec 15;55(6):864–872
  6. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007 Mar 20;146(6):406–415
  7. Yelin E. Is early intervention worth it?. J Rheumatol. 2005 Jan;(Suppl.):7236–7238
  8. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? health economics and the presidential candidates. N Engl J Med. 2008 Feb 14;358(7):661–663
  9. Drummond M, Stoddart G, Labelle R, Cushman R. Health economics: an introduction for clinicians. Ann Intern Med. 1987 Jul;107(1):88–92
  10. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 2003 Oct;48(10):2750–2762
  11. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000 Apr;29(5):305–320
  12. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 1999 Jun;42(6):1209–1218
  13. Rat A, Boissier M. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine. 2004 Nov;71(6):518–524
  14. Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Br Soc Rheumatology. 2000;
  15. Kapetanovic MC, Lindqvist E, Saxne T, Eberhardt K. Orthopaedic surgery in patients with rheumatoid arthritis over 20 years: prevalence and predictive factors of large joint replacement. Ann Rheum Dis. 2008 Oct;67(10):1412–1416
  16. Pynsent PB, Carter SR, Bulstrode CJK. The total cost of hip-joint replacement; a model for purchasers. J Public Health. 1996 Jun 1;18(2):157–168
  17. Verhoeven A, Bibo J, Boers M, et al. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoide Artritis. Rheumatology. 1998 Oct 1;37(10):1102–1109
  18. Van den Hout W, Goekoop-Ruiterman Y, Allaart C, et al. Cost-utility analysis of four treatment strategies for early rheumatoid arthritis: 2-year results of the best study. Ann Rheum Dis. 2006 Jul;65:507–508
  19. Mittendorf T, Dietz B, von der Schulenburg J, et al. Decreased resource utilization during long-term treatment with adalimumab in patients with long-standing RA. Arthritis Rheum. 2006 Sep;54(9):S115–S115
  20. Kirwan JR. Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J Rheumatol. 1999 Mar;26(3):720–725
  21. Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond). 2006 Jan 1;56(1):18–27
  22. Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(Suppl. 31):S71–S74
  23. Albers JM. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Br Soc Rheumatology. 1999;
  24. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis. 2002 Apr 1;61(4):335–340
  25. Lacaille D, Sheps S, Spinelli JJ, et al. Identification of modifiable work-related factors that influence the risk of work disability in rheumatoid arthritis. Arthritis Rheum. 2004;51(5):843–852
  26. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol. 1998 Nov;25(11):2108–2117
  27. Eberhardt K, Larsson B, Nived K, Lindqvist E. Work disability in rheumatoid arthritis–development over 15 years and evaluation of predictive factors over time. J Rheumatol. 2007 Mar;34(3):481–487
  28. Puolakka K, Kautiainen H, Pekurinen M, et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis. 2006 Jul 1;65(7):899–904
  29. Merkesdal S, Ruof J, Schoffski O, et al. Indirect medical costs in early rheumatoid arthritis. Arthritis Rheum. 2001;44:528–534
  30. Li X, Gignac MAM, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Medical Care. 2006;44(4):304
  31. Yelin E, Trupin L, Katz P, et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. 2003;48(11):3046–3054
  32. Smolen JS, Han C, Heijde DVD, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54(3):716–722
  33. van Vollenhoven R, Ferraccioli G, Breedveld F, et al. Effect of adalimumab combination therapy on work performance: Results from a companion study to PREMIER. Ann Rheum Dis. 2007 Jul;66(Suppl. 2):192–192
  34. Bejarano V, Quinn M, Conaghan P, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008 Oct 15;59(10):1467–74
  35. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008 Aug 2;372(9636):375–382
  36. Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol. 2004 May;31(5):849–855
  37. de Croon EM, Sluiter JK, Nijssen TF, et al. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2004 Nov 1;63(11):1362–1367
  38. Zhang W, Bansback N, Guh D, et al. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol. 2008 Sep;35(9):1729–1736
  39. Han C, Smolen J, Kavanaugh A, et al. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Care Res. 2008;59(4):510–514
  40. Puolakka K, Kautiainen H, Moettoenen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum. 2004;50(1):55–62
  41. Jacob-Tacken KHM, Koopmanschap MA, Meerding WJ, Severens JL. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Economics. 2005 May;14(5):435–443
  42. Nicholson S, Pauly MV, Polsky D, et al. Measuring the effects of workloss on productivity with team production. Health Economics. 2006 Feb;15(2):111–123
  43. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Economics. 1986 Mar;5(1):1–30
  44. Bansback N, Harrison M, Brazier J, et al. Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum. 2008 Jun 24;59(7):1018–1026
  45. Bansback N, Marra C, Tsuchiya A, et al. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57(6):963–971
  46. Symmons D, Mathers C, Pfleger B. The global burden of rheumatoid arthritis in the year 2000. Criterion. 12. Available from: http://aolsearch.aol.co.uk/aol/search?query = The%20global%20burden%20of%20rheumatoid%20arthritis%20in%20the%20year%202000&invocationType = sb_uk
  47. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2003 Jun;48(6):1530–1542
  48. Tan MCY, Regier DA, Esdaile JM, et al. Health economic evaluation: a primer for the practicing rheumatologist. Arthritis Rheum. 2006 Aug 15;55(4):648–656
  49. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998 Apr 1;18(2):S68–S80
  50. Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. PharmacoEconomics. 2005;23(5):423
  51. Griffith J, Carr A. What is the impact of early rheumatoid arthritis on the individual?. Best Pract Res Clin Rheumatol. 2001;15(1):77–90
  52. Eberhardt K, Larsson BM, Nived K. Early rheumatoid arthritis–some social, economical, and psychological aspects. Scand J Rheumatol. 1993;22(3):119–123
  53. Feldman DE, Bernatsky S, Haggerty J, et al. Delay in consultation with specialists for persons with suspected new-onset rheumatoid arthritis: a population-based study. Arthritis Rheum. 2007 Dec 15;57(8):1419–1425
  54. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008 Jan 15;148(2):124–134
  55. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 May 17;295(19):2275–2285
  56. Choy EHS, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford). 2005 Nov;44(11):1414–1421
  57. Buxton M, Drummond M, Van Hout B, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics. 1997;6217–6227
  58. Chen Y, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006 Nov;10(42):iii–iv, xi–xiii, 1–229
  59. Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-Effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol in press.
  60. Carol Black's review - Health work wellbeing. [cited 2008 Mar 19]. Available from: http://www.workingforhealth.gov.uk/Carol-Blacks-Review/
  61. Wolfe F, Michaud K. A brief introduction to the National Data Bank for rheumatic diseases. Clin Exp Rheumatol. 2005;23(5):168
  62. Kirwan JR. Links between radiological change, disability, and pathology in rheumatoid arthritis. J Rheumatol. 2001;28(4):881–886

PII: S1521-6942(08)00134-4

doi: 10.1016/j.berh.2008.11.005

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 1 , Pages 83-92 , February 2009

Article Tools

* Image Usage & Resolution